Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Klebsiella pneumoniae Infections Overview | 10 | 1 |
| Therapeutics Development | 11 | 2 |
| Pipeline Products for Klebsiella pneumoniae Infections Overview | 11 | 1 |
| Pipeline Products for Klebsiella pneumoniae Infections Comparative Analysis | 12 | 1 |
| Klebsiella pneumoniae Infections Therapeutics under Development by Companies | 13 | 2 |
| Klebsiella pneumoniae Infections Therapeutics under Investigation by Universities/Institutes | 15 | 1 |
| Klebsiella pneumoniae Infections Pipeline Products Glance | 16 | 3 |
| Late Stage Products | 16 | 1 |
| Clinical Stage Products | 17 | 1 |
| Early Stage Products | 18 | 1 |
| Klebsiella pneumoniae Infections Products under Development by Companies | 19 | 2 |
| Klebsiella pneumoniae Infections Products under Investigation by Universities/Institutes | 21 | 1 |
| Klebsiella pneumoniae Infections Companies Involved in Therapeutics Development | 22 | 22 |
| Appili Therapeutics Inc | 22 | 1 |
| Arsanis, Inc. | 23 | 1 |
| Cellceutix Corporation | 24 | 1 |
| Debiopharm International SA | 25 | 1 |
| Evaxion Biotech ApS | 26 | 1 |
| F. Hoffmann-La Roche Ltd. | 27 | 1 |
| FOB Synthesis, Inc. | 28 | 1 |
| Melinta Therapeutics, Inc | 29 | 1 |
| Merck &Co., Inc. | 30 | 1 |
| MicuRx Pharmaceuticals, Inc. | 31 | 1 |
| Nosopharm SAS | 32 | 1 |
| Peptilogics, Inc. | 33 | 1 |
| Pfizer Inc. | 34 | 1 |
| Phico Therapeutics Limited | 35 | 1 |
| Procarta Biosystems Limited | 36 | 1 |
| Sarepta Therapeutics, Inc. | 37 | 1 |
| Shionogi &Co., Ltd. | 38 | 1 |
| Soligenix, Inc. | 39 | 1 |
| Sumitomo Dainippon Pharma Co., Ltd. | 40 | 1 |
| Syntiron LLC | 41 | 1 |
| Tetraphase Pharmaceuticals Inc. | 42 | 1 |
| Varinel, Inc. | 43 | 1 |
| Klebsiella pneumoniae Infections Therapeutics Assessment | 44 | 9 |
| Assessment by Monotherapy Products | 44 | 1 |
| Assessment by Target | 45 | 2 |
| Assessment by Mechanism of Action | 47 | 2 |
| Assessment by Route of Administration | 49 | 2 |
| Assessment by Molecule Type | 51 | 2 |
| Drug Profiles | 53 | 49 |
| Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections Drug Profile | 53 | 1 |
| ASN-300 Drug Profile | 54 | 1 |
| ATI-1503 Drug Profile | 55 | 1 |
| CA-824 Drug Profile | 56 | 1 |
| CB-027 Drug Profile | 57 | 1 |
| CB-618 Drug Profile | 58 | 1 |
| CC-1807 Drug Profile | 59 | 1 |
| CTIX-1278 Drug Profile | 60 | 1 |
| Debio-1454 Drug Profile | 61 | 1 |
| dusquetide Drug Profile | 62 | 4 |
| FSI-1671 Drug Profile | 66 | 1 |
| FSI-1686 Drug Profile | 67 | 1 |
| GNEG SNARE Drug Profile | 68 | 1 |
| IBN-1 Drug Profile | 69 | 1 |
| klebsiella pneumonia vaccine Drug Profile | 70 | 1 |
| Klebsiella pneumoniae vaccine Drug Profile | 71 | 1 |
| Klebsiella pneumoniae vaccine Drug Profile | 72 | 1 |
| Klebsiella pneumoniae vaccine Drug Profile | 73 | 1 |
| mirandamycin Drug Profile | 74 | 1 |
| MRX-V Drug Profile | 75 | 1 |
| NOSO-95179 Drug Profile | 76 | 1 |
| Onc-72 Drug Profile | 77 | 1 |
| Peptides for Infectious Diseases Drug Profile | 78 | 1 |
| PMX-100 Drug Profile | 79 | 1 |
| PMX-1091 Drug Profile | 80 | 1 |
| PMX-1142 Drug Profile | 81 | 1 |
| PMX-229 Drug Profile | 82 | 1 |
| PMX-633 Drug Profile | 83 | 1 |
| PT-4 Drug Profile | 84 | 1 |
| RX-05 Drug Profile | 85 | 1 |
| RXP-873 Drug Profile | 86 | 1 |
| S-649266 Drug Profile | 87 | 2 |
| SM-295291 Drug Profile | 89 | 1 |
| SM-369926 Drug Profile | 90 | 1 |
| Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections Drug Profile | 91 | 1 |
| Small Molecules for Bacterial Infections Drug Profile | 92 | 1 |
| Small Molecules for Bacterial Infections Drug Profile | 93 | 1 |
| Small Molecules for Klebsiella pneumoniae Infections Drug Profile | 94 | 1 |
| Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections Drug Profile | 95 | 1 |
| Small Molecules to Inhibit DHFR for Infectious Diseases Drug Profile | 96 | 2 |
| SPR-741 Drug Profile | 98 | 1 |
| Synthetic Peptide for Gram-Negative Bacterial Infections Drug Profile | 99 | 1 |
| TP-6076 Drug Profile | 100 | 1 |
| VAR-10100 Drug Profile | 101 | 1 |
| Klebsiella pneumoniae Infections Dormant Projects | 102 | 2 |
| Klebsiella pneumoniae Infections Discontinued Products | 104 | 1 |
| Klebsiella pneumoniae Infections Product Development Milestones | 105 | 2 |
| Featured News &Press Releases | 105 | 1 |
| Jun 17, 2016: Arsanis Presents Data at ASM Microbe 2016 Demonstrating Protection Against Klebsiella pneumoniae using Monoclonal Antibody Technology | 105 | 1 |
| Mar 09, 2015: Phico Therapeutics Receives Translation Award to Advance its SASPject PT4 Aimed at Escherichia coli and Klebsiella pneumoniae Towards Clinical Trials | 105 | 1 |
| Sep 06, 2012: Cubist Pharma To Feature Antibiotic Drug Candidate CB-027 At ICAAC 2012 | 106 | 1 |
| Appendix | 107 | 2 |
| Methodology | 107 | 1 |
| Coverage | 107 | 1 |
| Secondary Research | 107 | 1 |
| Primary Research | 107 | 1 |
| Expert Panel Validation | 107 | 1 |
| Contact Us | 107 | 1 |
| Disclaimer | 108 | 1 |